


10/056,298

-2-

A0000506-01-DRK

Amendments to the Claims:

1. (Cancelled)
2. (Currently Amended) A method for ~~preventing or treating~~ gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV;



or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

3. (Currently Amended) The method of Claim 1 or 2, wherein the compound is selected from:
 - (1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
 - (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
 - (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
 - (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
 - (1 α ,3 α ,5 α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
 - (1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
 - (1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
 - (1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
 - (1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
 - (1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
 - (1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
 - (1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,

10/056,298

-3-

A0000506-01-DRK

(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 α ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 α)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 α)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,

10/056,298

-4-

A0000506-01-DRK

((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, and
((2R,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) The method according to Claim 1 or 2, where n the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.
5. (Cancelled)

10/056,298

-5-


A0000506-01-DRK

6. (Currently Amended) A method for ~~preventing or~~ treating gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of (1~~α~~+3~~α~~+5~~α~~)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.
7. (Currently Amended) The method according to any one of Claims 2, 3, 4 and 5 to 6, wherein the disorder is functional bowel disorder or inflammatory bowel disease.
8. (Original) The method according to Claim 7, wherein the functional bowel disorder is gastro-esophageal reflux, dyspepsia, irritable bowel syndrome or functional abdominal pain syndrome.
9. (Original) The method according to Claim 7, wherein the inflammatory bowel disease is Crohn's disease, ileitis or ulcerative colitis.
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Previously Added) A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:

10/056,298

-6-

A0000506-01-DRK



or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

16. (Previously Added) The method of Claim 15, wherein the compound is selected from:

- (1 α ,6 α ,8 β)-(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
- (1 α ,3 α ,5 α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
- (1 α ,5 β)-(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
- (1 α ,5 β)-(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
- (1 α ,5 β)-(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (1 α ,6 β)-(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (1 α ,7 β)-(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
- (1 α ,5 β)-(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
- (1 α ,5 β)-(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
- (1 α ,5 β)-(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (1 α ,6 β)-(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (1 α ,7 β)-(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
- (1 α ,3 α ,5 α)-(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
- (1 α ,3 α ,5 α)-(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (1 α ,6 α ,8 α)-(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (1 α ,7 α ,9 α)-(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
- (1 α ,3 β ,5 α)-(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,

10/056,298

-7-

A0000506-01-DRK

(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,

10/056,298

-8-

A0000506-01-DRK

((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((2S,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((2S,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid, and
((2R,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
or a pharmaceutically acceptable salt thereof.

17. (Previously Added) The method according to Claim 15, wherein the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.
18. (Currently Amended) A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of
(1 α -(3 α -(5 α))-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.
19. (Previously Added) A pharmaceutical composition for the treatment of irritable bowel syndrome of comprising a compound of formula I-IV.
20. (Currently Amended) The pharmaceutical composition according to claim 19 comprising (1 α -(3 α -(5 α))-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid.